(Tromsø, 25 August 2017) Biotec Pharmacon ASA's ("Biotec", OSE: BIOTEC)
subsidiary Biotec BetaGlucans has today signed a Term Sheet to supply M-Gard® to
a US customer for consumer health applications
Biotec BetaGlucans AS has signed a Term Sheet agreement to enter into a business
relationship with a US-company, for deliveries of its M-Gard®-ingredient for use
in their consumer health products.
Deliveries will start immediately while the parties work on the complementary
Supply Agreement. According to the Term Sheet signed, the customer will receive
certain rights based on a minimum purchase volume of NOK 12 mill over the 3
years initial term.
"We have been exploring the possibility to re-enter the consumer health market
with our beta-glucan ingredient M-Gard® over the last months and have received
positive feedback from several potential customers. This Term Sheet represent
the first agreement where Biotec BetaGlucans provides bulk ingredient intended
for end-user products sold in the US market. It will also provide an important
reference to re-establish ourselves as a long-term supplier to this industry,"
says Biotec Pharmacon's CEO Svein W. F. Lien.
For more information, please contact:
CEO Svein W. F. Lien, tel +47 922 89 323
About Biotec BetaGlucans AS:
Biotec BetaGlucans is a wholly owned subsidiary of Biotec Pharmacon ASA. Biotec
BetaGlucans develops and manufactures novel immunomodulating products for
business areas including Woulgan®, a premium priced product in the advanced
wound care market, animal feed, consumer health, cosmetics, medical devices and
pharmaceuticals. M-Gard® particulate is Biotec BetaGlucans' flagship product for
immune-related consumer health applications. For more information please visit
our company website at https://biotec.no/ or our M-Gard®-product website at
https://m-gard.com/.
About Biotec Pharmacon ASA:
Biotec Pharmacon ASA is the parent company of Biotec BetaGlucans AS and
ArcticZymes AS. ArcticZymes develops, produces and markets enzymes of marine
origin used in molecular DNA technologies and diagnostics, representing growth
markets where rapid technological developments are creating a strong demand for
new and improved enzymes.